支持与应用
Mogrol represents a novel leukemia therapeutic,
发布时间：
2019-02-14
Introduction
Leukemia is a malignant disease of blood cellforming tissues. Unlike solid tumors, malignant hematological tumors cannot be cured by surgical treatment or radiation therapy. Therefore,chemotherapy is the main strategy for leukemia treatment [1]. However, over time, leukemia cells can show a reduced sensitivity to cytotoxic drugs, leading to multi drug resistance. Furthermore, currently available chemotherapeutics can induce adverse side effects[2]. Thus, it is imperative to identify novel chemotherapeutic agents that treat leukemia while minimizing adverse effects.
Increased knowledge of the molecular mechanisms underlying cancer may provide novel
molecular targets for therapeutic intervention [3]. The ERK cascade is primarily activated by growth factors, and is critical for proliferation and survival [4]. Signal transducer and activator of transcription 3 (STAT3) is another wellknown oncogene that is constitutively activated in many human cancers [5]. Emerging literature suggests that ERK and STAT3 signaling may play a critical role in cancer formation and progression [6, 7]. Furthermore, aberrant activation of the ERK pathway [8, 9] and constitutively active STAT3 is frequently found in leukemia [10, 11]. Thus, targeting STAT3 or ERK with novel, low-toxicity anticancer compounds could be promising for leukemia treatment.